| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Committee on Cancer Biology, University of Chicago, Chicago, Illinois and 2 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland
Requests for reprints: Charles M. Rudin, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Bunting Blaustein Cancer Research Building, Room 344, 1650 Orleans Street, Baltimore, MD 21231. Phone: 410-955-8904; Fax: 410-502-0677. E-mail: rudin{at}jhmi.edu
Chemotherapeutic agents induce apoptosis in cancer cells through effects on multiple intracellular targets. Recent observations suggest that a consistent cellular response to chemotherapeutic agents of disparate classes is down-regulation of glycolytic metabolism. Inhibition of glycolytic activity has been linked to apoptotic induction in several models. The serine/threonine kinase Akt (protein kinase B) promotes both glycolytic metabolism and survival, and these functions have been shown to be linked. Because of its key role in both glycolysis and survival, we examined the function of Akt in the cellular response to cytotoxic agents. Following exposure to any of several chemotherapeutic agents, an initial up-regulation in endogenous Akt activity is rapidly suppressed. Using cells containing constitutively active myristoylated Akt, dominant-negative kinase-dead Akt, or an empty vector control, we show here that Akt activation markedly increases resistance to microtubule-directed agents, including vincristine, colchicine, and paclitaxel. Akt also maintains increased glycolytic rate in response to antimicrotubule treatment. Rapamycin inhibits Akt-mediated maintenance of glycolysis and therapeutic resistance, indicating that these effects are dependent on mammalian target of rapamycin (mTOR). Furthermore, an activated mTOR mutant confers resistance to antimicrotubule agents. Taken together, these observations suggest that activation of the Akt-mTOR signaling pathway can augment glucose utilization and promote resistance to chemotherapeutic agents that do not directly target metabolic regulation. These data provide insight into potentially synergistic combinations of anticancer therapies.
Key Words: apoptosis • chemotherapy • glycolysis • vincristine • Akt
Grant support: NIH grant K08 CA81134 (C.M. Rudin).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to 1indicate this fact.
Received 7/22/04; revised 9/14/04; accepted 10/ 7/04.
This article has been cited by other articles:
|
|
 |
|
  D. Marimpietri, C. Brignole, B. Nico, F. Pastorino, A. Pezzolo, F. Piccardi, M. Cilli, D. Di Paolo, G. Pagnan, L. Longo, et al. Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis Clin. Cancer Res., July 1, 2007; 13(13): 3977 - 3988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Z. Cheng, J. Chan, Q. Wang, W. Zhang, C. D. Sun, and L.-H. Wang Twist Transcriptionally Up-regulates AKT2 in Breast Cancer Cells Leading to Increased Migration, Invasion, and Resistance to Paclitaxel Cancer Res., March 1, 2007; 67(5): 1979 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Fujiwara, Y. Hosokawa, K. Watanabe, S. Tanimura, K.-i. Ozaki, and M. Kohno Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated Mol. Cancer Ther., March 1, 2007; 6(3): 1133 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty and K. I. Block Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy. Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268. [Abstract] [PDF]
|
|
|
|
|
|
J. Ramos, M. Sirisawad, R. Miller, and L. Naumovski Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation Mol. Cancer Ther., May 1, 2006; 5(5): 1176 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sunters, P. A. Madureira, K. M. Pomeranz, M. Aubert, J. J. Brosens, S. J. Cook, B. M.T. Burgering, R. C. Coombes, and E. W.-F. Lam Paclitaxel-Induced Nuclear Translocation of FOXO3a in Breast Cancer Cells Is Mediated by c-Jun NH2-Terminal Kinase and Akt Cancer Res., January 1, 2006; 66(1): 212 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Isakoff, J. A. Engelman, H. Y. Irie, J. Luo, S. M. Brachmann, R. V. Pearline, L. C. Cantley, and J. S. Brugge Breast Cancer-Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells Cancer Res., December 1, 2005; 65(23): 10992 - 11000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. VanderWeele and C. M. Rudin Mammalian Target of Rapamycin Promotes Vincristine Resistance through Multiple Mechanisms Independent of Maintained Glycolytic Rate Mol. Cancer Res., November 1, 2005; 3(11): 635 - 644. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
